Diana Whitmore


I provide strategic advice to help companies obtain financing and navigate business challenges.

Diana Whitmore advises clients on corporate finance and bank lending, and she frequently counsels private funds in fund financing. Diana’s corporate work also extends to general corporate matters, including private equity and venture capital financings and mergers and acquisitions.

Prior to attending law school, she worked as a consultant at Deloitte and Accenture, allowing her to draw on her consulting background when offering clients advice on complicated matters.


  • Boston College Law School, J.D.
  • Vanderbilt University, B.S.

Bar and Court Admissions

  • Massachusetts



  • A market-leading middle-market lender with over $40 billion under management, in fund financing for various funds and business development companies 
  • A private credit investment firm with over $18 billion in capital, in fund financings
  • A lower-middle market private investment firm, in an acquisition financing for healthcare services company
  • A market-leading middle-market lender with over $30 billion under management
  • Ascend Wellness Holdings, Inc. (CSE: AAWH.U, OTCQX: AAWH), a leading multi-state, vertically integrated cannabis operator, in additional funding to support investments and acquisitions under its senior secured term loan with Seaport Global Securities LLC as lead manager
  • A cannabis business lender, in its loan to a fast-growing cannabis store chain


  • Kula Bio, a leader in sustainable nitrogen solutions, in a $50 million Series A financing
  • Prelude Research, a cyberdefense technology company, in a $24 million Series A financing
  • TireTutor, an operator of a marketplace platform for car tires, in a Series Seed investment
  • Venture capital firm CRV as lead investor in a Series Seed financing for a financial services platform


  • Datadog (Nasdaq: DDOG), a monitoring and security platform for cloud applications, in its acquisition of CoScreen
  • Alexion, a global biopharmaceutical company and subsidiary of AztraZeneca, in its acquisition of Caelum Biosciences for $150 million